ADMA Biologics, Inc. (ADMA)
9.345
-0.14
(-1.42%)
USD |
NASDAQ |
Aug 28, 16:00
9.345
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Cash from Operations (Quarterly) : 29.54M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.54M |
| March 31, 2026 | 58.25M |
| December 31, 2025 | 35.64M |
| September 30, 2025 | 13.29M |
| June 30, 2025 | 21.14M |
| March 31, 2025 | -19.68M |
| December 31, 2024 | 50.22M |
| September 30, 2024 | 25.03M |
| June 30, 2024 | 45.65M |
| March 31, 2024 | -2.218M |
| December 31, 2023 | 17.60M |
| September 30, 2023 | 11.99M |
| June 30, 2023 | -6.059M |
| March 31, 2023 | -14.72M |
| December 31, 2022 | -7.379M |
| September 30, 2022 | -13.28M |
| June 30, 2022 | -12.83M |
| March 31, 2022 | -26.01M |
| December 31, 2021 | -33.47M |
| September 30, 2021 | -13.41M |
| June 30, 2021 | -32.26M |
| March 31, 2021 | -33.23M |
| December 31, 2020 | -32.22M |
| September 30, 2020 | -23.85M |
| June 30, 2020 | -21.28M |
| Date | Value |
|---|---|
| March 31, 2020 | -24.65M |
| December 31, 2019 | -19.65M |
| September 30, 2019 | -23.63M |
| June 30, 2019 | -18.62M |
| March 31, 2019 | -14.29M |
| December 31, 2018 | -18.79M |
| September 30, 2018 | -12.54M |
| June 30, 2018 | -14.91M |
| March 31, 2018 | -16.43M |
| December 31, 2017 | -13.36M |
| September 30, 2017 | -9.739M |
| June 30, 2017 | -8.775M |
| March 31, 2017 | -5.398M |
| December 31, 2016 | -3.614M |
| September 30, 2016 | -4.683M |
| June 30, 2016 | -4.804M |
| March 31, 2016 | -5.168M |
| December 31, 2015 | -4.078M |
| September 30, 2015 | -2.673M |
| June 30, 2015 | -4.446M |
| March 31, 2015 | -4.221M |
| December 31, 2014 | -2.902M |
| September 30, 2014 | -2.466M |
| June 30, 2014 | -4.296M |
| March 31, 2014 | -5.040M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Erasca, Inc. | -27.27M |
| Krystal Biotech, Inc. | 74.79M |
| Vericel Corp. | 16.19M |
| Emergent BioSolutions, Inc. | 56.10M |
| Exelixis, Inc. | 307.74M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.256M |
| Cash from Financing (Quarterly) | -29.42M |
| Free Cash Flow | 116.22M |
| Free Cash Flow Per Share (Quarterly) | 0.1184 |
| Free Cash Flow to Equity (Quarterly) | 27.85M |
| Free Cash Flow to Firm (Quarterly) | 29.86M |
| Free Cash Flow Yield | 5.19% |